文献速递肝病

胆管细胞来源外泌体长链非编码RNA H19在小鼠和人类中促进胆汁淤积性肝损伤

Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.
PubMed 文献 · Hepatology · 2018-05-02

研究报道胆管细胞来源外泌体将长链非编码RNA H19转移至肝细胞并促进胆汁淤积性肝损伤。肝内H19水平与Mdr2-/-小鼠、CCl4诱导小鼠及人类原发性硬化性胆管炎患者胆汁淤积性肝损伤严重程度相关,血清外泌体H19随疾病进展逐渐上调。携带H19的外泌体抑制肝细胞小异二聚体伴侣表达,移植老年纤维化Mdr2-/-小鼠血清外泌体可促进年轻Mdr2-/-小鼠肝纤维化。

要点

  • 胆管细胞来源外泌体将H19转移至肝细胞并促进胆汁淤积性肝损伤。
  • 血清外泌体H19水平在Mdr2-/-小鼠和肝硬化患者疾病进展中逐渐上调。
  • 移植老年纤维化Mdr2-/-小鼠血清外泌体可促进年轻Mdr2-/-小鼠肝纤维化。

核心结论

  • 胆管细胞来源外泌体H19在胆汁淤积性肝损伤中起关键作用,血清外泌体H19代表一种非侵入性生物标志物和胆汁淤积性疾病的潜在治疗靶点。

研究设计与样本

  • 研究采用纤维化小鼠模型(包括Mdr2-/-小鼠,一种特征明确的原发性硬化性胆管炎模型,或CCl4诱导的胆汁淤积性肝损伤小鼠模型)以及人类原发性硬化性胆管炎患者。

主要发现

  • 肝内H19水平与Mdr2-/-小鼠、CCl4诱导的胆汁淤积性肝损伤小鼠模型及人类原发性硬化性胆管炎患者的胆汁淤积性损伤严重程度相关。
  • 血清外泌体H19水平在Mdr2-/-小鼠和肝硬化患者的疾病进展过程中逐渐上调。
  • 来自野生型小鼠原代胆管细胞的携带H19的外泌体抑制肝细胞中小异二聚体伴侣的表达,而来自H19-/-小鼠胆管细胞的外泌体无此作用。
  • H19过表达在转录和转录后水平显著抑制小异二聚体伴侣表达。
  • 移植老年纤维化Mdr2-/-小鼠的携带H19的血清外泌体显著促进年轻Mdr2-/-小鼠的肝纤维化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Cholestatic liver injury is an important clinical problem with limited understanding of disease pathologies. Exosomes are small extracellular vesicles released by a variety of cells, including cholangiocytes. Exosome-mediated cell-cell communication can modulate various cellular functions by transferring a variety of intracellular components to target cells. Our recent studies indicate that the long noncoding RNA (lncRNA), H19, is mainly expressed in cholangiocytes, and its aberrant expression is associated with significant down-regulation of small heterodimer partner (SHP) in hepatocytes and cholestatic liver injury in multidrug resistance 2 knockout (Mdr2-/- ) mice. However, how cholangiocyte-derived H19 suppresses SHP in hepatocytes remains unknown. Here, we report that cholangiocyte-derived exosomes mediate transfer of H19 into hepatocytes and promote cholestatic injury. Hepatic H19 level is correlated with severity of cholestatic injury in both fibrotic mouse models, including Mdr2-/- mice, a well-characterized model of primary sclerosing cholangitis (PSC), or CCl4 -induced cholestatic liver injury mouse models, and human PSC patients. Moreover, serum exosomal-H19 level is gradually up-regulated during disease progression in Mdr2-/- mice and patients with cirrhosis. H19-carrying exosomes from the primary cholangiocytes of wild-type (WT) mice suppress SHP expression in hepatocytes, but not the exosomes from the cholangiocytes of H19-/- mice. Furthermore, overexpression of H19 significantly suppressed SHP expression at both transcriptional and posttranscriptional levels. Importantly, transplant of H19-carrying serum exosomes of old fibrotic Mdr2-/- mice significantly promoted liver fibrosis (LF) in young Mdr2-/- mice. CONCLUSION: Cholangiocyte-derived exosomal-H19 plays a critical role in cholestatic liver injury. Serum exosomal H19 represents a noninvasive biomarker and potential therapeutic target for cholestatic diseases. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Li X, Liu R, Huang Z, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology. 2018. PMID: 29425397. doi:10.1002/hep.29838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。